Risk stratification for secondary prevention with ticagrelor and aspirin: A closer look to patient subsets from the PEGASUS-TIMI 54 trial

In the PEGASUS trial, 21,162 patients with a history of myocardial infarction within 1 to 3years earlier were randomized to ticagrelor 90mg twice daily, ticagrelor 60mg twice daily or placebo on a background of low-dose aspirin, and were followed for a median of 33months [1]. Both doses of ticagrelor significantly reduced the primary efficacy endpoint (a composite of cardiovascular death, myocardial infarction, or stroke) but also increased the primary safety endpoint (TIMI major bleeding), compared with placebo [1].

Source: International Journal of Cardiology - August 5, 2015 Category: Cardiology Authors: Davide Capodanno, Piera Capranzano, Sergio Buccheri, Corrado Tamburino Tags: Letter to the Editor Source Type: research